health
sent home during the deadliest window
No validated wearable exists for detecting postpartum maternal sepsis during the highest-risk period
Problem statement
One-third of maternal deaths and 50% of maternal sepsis cases occur in the postpartum period — after hospital discharge when clinical monitoring stops. No validated wearable or remote monitoring tool exists for detecting postpartum sepsis, despite clear physiological markers (temperature, heart rate, respiratory rate) that could signal early infection. Standard sepsis screening tools (SIRS criteria, qSOFA) use vital sign thresholds developed for non-pregnant populations that are inappropriate for postpartum physiology, where baseline heart rate, temperature, and white blood cell counts are naturally elevated for weeks after delivery.
Why this matters
Maternal mortality in the US reached 32.9 deaths per 100,000 live births in 2021, with sepsis among the leading preventable causes. Most postpartum sepsis deaths are preventable with early detection and antibiotic treatment, but the current care model discharges mothers 24–72 hours after delivery with a single follow-up visit at 6 weeks — creating a surveillance gap during the highest-risk window. Disparities compound the problem: Black women are three times more likely to die from pregnancy-related causes, and rural mothers may be hours from the nearest obstetric facility.
What’s been tried and why it hasn’t worked
General-purpose wearable health monitors (Fitbit, Apple Watch) track heart rate and activity but are not validated for postpartum sepsis detection and do not incorporate pregnancy-adjusted vital sign thresholds. A resting heart rate of 100 bpm that would trigger an alert in a non-pregnant adult is within normal postpartum range. Hospital-based early warning scores (MEOWS — Modified Early Obstetric Warning System) exist but are designed for inpatient use and cannot be applied to home monitoring because they require clinical interpretation and vital sign equipment. Research studies on postpartum remote monitoring are in early pilot phases with no validated algorithm for sepsis detection specifically.
What would unlock progress
Pregnancy-and-postpartum-adjusted vital sign algorithms that define sepsis alert thresholds calibrated to the physiological changes of the postpartum period. Clinical validation studies establishing the positive predictive value of wearable-detected physiological changes for postpartum sepsis. Integration pathways that connect home monitoring alerts to clinical teams without overwhelming provider workflows or generating excessive false alarms — the alert must be specific enough to trigger action.
Entry points for student teams
A student team could build the pregnancy-adjusted threshold logic out of the published record instead of out of patient data: several MEOWS validation studies report their trigger parameters together with sensitivity and specificity in obstetric cohorts (Singh et al., Anaesthesia 2012;67(1):12–18; Ryan et al., J Obstet Gynaecol Can 2017;39(9):728–733; Singhal et al., J Family Med Prim Care 2022;11(12):7644–7651; Kefeli Çelik et al., Ulus Travma Acil Cerrahi Derg 2024;30(9):635–643; Werlang et al., J Obstet Gynaecol Can 2026;48(4):103248), so a team can work out which parameters carry the discrimination, re-specify them for the weeks at home rather than the inpatient ward, and test the resulting rule against published case series of postpartum sepsis presentations. Alternatively, teams could design a prototype wearable alert system using commercially available sensors (temperature, pulse, respiratory rate) with postpartum-specific detection algorithms — and because a real accuracy study needs enrolled postpartum patients, the semester deliverable is the validation trial's design rather than its execution: sampling frame, reference standard for sepsis, the alert-to-clinician escalation path, and a pre-registered analysis plan sized to the event rate, handed to a clinical partner. Analyzing hospital continuous postpartum vital-sign records is a real third door but not an open one: those are identifiable clinical records rather than a public dataset, and reaching them takes an IRB protocol plus a sponsoring obstetric service or hospital-informatics group that already owns the monitoring archive. Relevant disciplines: biomedical engineering, clinical informatics, data science, obstetric medicine.
Genome — every gene is a door
Structural cousins — same reason stuck, other fields
Sources
National Academies of Sciences, Engineering, and Medicine, "Advancing Diagnostic Excellence in Maternal Health Care," workshop proceedings, 2023; Forum on Advancing Diagnostic Excellence, Board on Health Care Services; accessed 2026-02-20
verification notes (working record)
The collection team’s own sourcing notes for this brief, kept verbatim:
No existing maternal health brief in the collection. Distinct from general health monitoring briefs by the specific physiological problem: pregnancy-adjusted baselines invalidate standard screening tools, creating a false choice between high false-alarm rates (standard thresholds) and missed sepsis (no monitoring). Related to `health-neonatal-sepsis-diagnostic-lmic-gap` (similar diagnostic challenge in a different population) and `health-multiplexed-biosensor-field-translation` (wearable sensor translation). Source-bias note: NASEM diagnostic excellence forum frames this as a diagnostic systems gap; the binding constraints include the technical problem of pregnancy-adjusted algorithms AND the care model that stops monitoring at discharge (wrong-stakeholder pattern — surveillance system designed around hospital workflows rather than patient risk windows).
Reconciliation 2026-08-21: Entry-point realism repair (`verification/ENTRY-POINT-REALISM-TRIAGE-2026-08-21.md`, score 3). The triage flag is CONFIRMED: the first door asked students to "analyze existing datasets of postpartum vital signs (from hospitals that continuously monitor patients before discharge)," which describes identifiable clinical records under HIPAA, not an obtainable dataset — there is no open corpus of continuous postpartum vitals with sepsis outcomes, and the usual credentialed fallback does not rescue it (MIMIC-IV's continuous vital-sign records come from adult medical and surgical ICUs, where postpartum sepsis patients are essentially absent, and access is credentialed rather than public in any case). Repair: that door is replaced with a literature-derived one that reaches the same deliverable — the pregnancy-adjusted threshold logic — using published MEOWS validation studies that report trigger parameters with diagnostic accuracy. Five were verified as real and citable through the Europe PMC REST record search for TITLE:"Modified Early Obstetric Warning System" (https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=TITLE%3A%22Modified%20Early%20Obstetric%20Warning%20System%22&format=json&resultType=core): Singh S, McGlennan A, England A, Simons R, "A validation study of the CEMACH recommended modified early obstetric warning system (MEOWS)," Anaesthesia 2012;67(1):12–18, doi:10.1111/j.1365-2044.2011.06896.x, PMID 22066604 (89% sensitive, 79% specific); Ryan HM et al., J Obstet Gynaecol Can 2017;39(9):728–733.e3, doi:10.1016/j.jogc.2017.01.028, PMID 28566256; Singhal S et al., J Family Med Prim Care 2022;11(12):7644–7651, doi:10.4103/jfmpc.jfmpc_320_22, PMID 36994023; Kefeli Çelik H et al., Ulus Travma Acil Cerrahi Derg 2024;30(9):635–643, doi:10.14744/tjtes.2024.87099, PMID 39222490; Werlang A et al., J Obstet Gynaecol Can 2026;48(4):103248, doi:10.1016/j.jogc.2026.103248, PMID 41722649. The wearable-prototype door was kept but brought under the design-the-trial default — a wearable accuracy study requires enrolled postpartum patients, so the semester deliverable is now the validation trial's design (sampling frame, sepsis reference standard, escalation path, pre-registered analysis plan) handed to a clinical partner. The hospital-records door is retained as an honest third door with an explicit access line naming the IRB protocol and the sponsoring obstetric or hospital-informatics owner. Genome tags untouched.